Emerging data suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may offer a notable step forward for weight loss . Early patient trials have demonstrated considerable decreases in visceral mass , potentially outperforming existing body composition medications . Nevertheless , more evalu